Alaa Atamna

Dr. Alaa Atamna


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
GAGida Ayada
Gida Ayada
YEYonatan Edel
Yonatan Edel
ABAlon Burg
Alon Burg
ABAdi Bachar
Adi Bachar
YHYehiel Hayun
Yehiel Hayun
AEAvishay Elis
Avishay Elis

9 July 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
MEMeital Elbaz
Meital Elbaz
MKMaya Korem
Maya Korem
OAOshrat Ayalon
Oshrat Ayalon
YWYonit Wiener-Well
Yonit Wiener-Well
Yael Shachor-MeyouhasYael Shachor-Meyouhas
Yael Shachor-Meyouhas
RBRonen Ben-Ami
Ronen Ben-Ami
Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence of clinically important fungal diseases in hospitalized COVID-19 patients during the first year of the pandemic. We performed a multicenter survey of IFDs among patients hospitalized with COVID-19 in 13 hospitals in Israel between February 2020 and May 2021. COVID-19-associated pulmonary mold disease (PMD) and invasive candidiasis (IC) were defined using ECMM/ISHAM and EORTC/MSG criteria, respectively. Overall rates of IC and PMD among patients with critical COVID-19 were 10.86 and 10.20 per 1000 admissions, respectively, with significant variability among medical centers. PMD rates were significantly lower in centers where galactomannan was a send-out test versus centers with on-site testing (p = 0.035). The 30-day mortality rate was 67.5% for IC and 57.5% for PMD. Treatment with an echinocandin for IC or an extended-spectrum azole for PMD was associated with significantly lower mortality rates (adjusted hazard ratio [95% confidence interval], 0.26 [0.07–0.91] and 0.23 [0.093–0.57], respectively). In this multicenter national survey, variable rates of PMD were associated with on-site galactomannan testing, suggesting under-detection in sites lacking this capacity. COVID-19-related IFDs were associated with high mortality rates, which were reduced with appropriate antifungal therapy.